RCUS Stock Analysis: Arcus Biosciences | NYSE
Biotechnology | NYSE, USA | Market Cap: 3.815m USD | 12M Return: 268% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.1M
Qual. Beats: 0
Rev. Trend: 64.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 8.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arcus Biosciences (RCUS) is a clinical-stage biopharmaceutical company headquartered in Hayward, California, founded in 2015 and listed on the NYSE since 2018. The company is focused on developing and commercializing cancer therapies, primarily in the United States, with a pipeline that includes small molecules and antibodies targeting immune and tumor metabolism pathways.
Its development portfolio spans several oncology indications: Casdatifan (HIF-2a inhibitor, kidney cancer); Domvanalimab (anti-TIGIT antibody, lung and gastrointestinal cancers); Zimberelimab (anti-PD-1 antibody); Quemliclustat (CD73 inhibitor, lung and pancreatic cancer); AB598 (CD39 antibody, gastrointestinal cancer); and AB801 (AXL inhibitor, lung cancer). The company has established clinical collaborations with AstraZeneca, BVF Partners, and Bristol-Myers Squibb to advance multiple programs, including combination regimens in non-small cell lung cancer and kidney cancer.
As a clinical-stage biotech, Arcus has not yet generated product revenue and relies on capital markets and partner funding to finance its R&D operations. Biotechnology companies at this stage typically face long development timelines, high cash burn, and dependency on clinical trial outcomes and regulatory approvals for future commercialization.
- Domvanalimab Phase 3 lung cancer data readout with AstraZeneca
- Casdatifan Phase 2 kidney cancer results drive expansion plans
- Cash runway extension supports pipeline through key 2026 catalysts
| Net Income: -369.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA -22.84 > 1.0 |
| NWC/Revenue: 269.1% < 20% (prev 595.0%; Δ -326.0% < -1%) |
| CFO/TA -0.49 > 3% & CFO -488.0m > Net Income -369.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.4m) vs 12m ago 27.44% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 21.92% > 50% (prev 12.20%; Δ 9.73% > 0%) |
| Interest Coverage Ratio: -15.41 > 6 (EBIT TTM -339.0m / Interest Expense TTM 22.0m) |
| A: 0.64 (Total Current Assets 844.0m - Total Current Liabilities 209.0m) / Total Assets 997.0m |
| B: -1.62 (Retained Earnings -1.61b / Total Assets 997.0m) |
| C: -0.31 (EBIT TTM -339.0m / Avg Total Assets 1.08b) |
| D: 1.11 (Book Value of Equity 524.0m / Total Liabilities 473.0m) |
| Altman-Z'' = -2.05 = D |
| DSRI: 0.20 (Receivables 7.00m/21.0m, Revenue 236.0m/141.0m) |
| GMI: 0.97 (GM 92.91% / 96.19%) |
| AQI: 1.69 (AQ_t 0.12 / AQ_t-1 0.07) |
| SGI: 1.67 (Revenue 236.0m / 141.0m) |
| TATA: 0.12 (NI -369.0m - CFO -488.0m) / TA 997.0m) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 30.25 with a total of 794,169 shares traded. Over the past week, the price has changed by -2.67%, over one month by +29.72%, over three months by +37.06% and over the past year by +268.00%.
Current recommended Stop Loss: 28.10 (which is 7.1% or 1.3 ATR below the current price).
Arcus Biosciences has received a consensus analysts rating of 4.46. Therefore, it is recommended to buy RCUS.
- StrongBuy: 8
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.8 | 18.2% |
P/S = 16.164
P/B = 7.28
Revenue TTM = 236.0m USD
EBIT TTM = -339.0m USD
EBITDA TTM = -330.0m USD
Long Term Debt = 100.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.0m USD (from shortTermDebt, last quarter)
Debt = 126.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.0m
Net Debt = -696.0m USD (calculated: Debt 126.0m - CCE 822.0m)
Enterprise Value = 3.12b USD (3.81b + Debt 126.0m - CCE 822.0m)
Interest Coverage Ratio = -15.41 (Ebit TTM -339.0m / Interest Expense TTM 22.0m)
EV/FCF = -6.38x (Enterprise Value 3.12b / FCF TTM -489.0m)
FCF Yield = -15.68% (FCF TTM -489.0m / Enterprise Value 3.12b)
FCF Margin = -207.2% (FCF TTM -489.0m / Revenue TTM 236.0m)
Net Margin = -156.4% (Net Income TTM -369.0m / Revenue TTM 236.0m)
Gross Margin = unknown ((Revenue TTM 236.0m - Cost of Revenue TTM 9.00m) / Revenue TTM)
Tobins Q-Ratio = 3.13 (Enterprise Value 3.12b / Total Assets 997.0m)
Interest Expense / Debt = 17.46% (Interest Expense 22.0m / Debt 126.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -267.8m (EBIT -339.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.04 (Total Current Assets 844.0m / Total Current Liabilities 209.0m)
Debt / Equity = 0.24 (Debt 126.0m / totalStockholderEquity, last quarter 524.0m)
Debt / EBITDA = 2.11 (negative EBITDA) (Net Debt -696.0m / EBITDA -330.0m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -696.0m / FCF TTM -489.0m)
Total Stockholder Equity = 535.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.28% (Net Income -369.0m / Total Assets 997.0m)
RoE = -68.97% (Net Income TTM -369.0m / Total Stockholder Equity 535.0m)
RoCE = -53.39% (EBIT -339.0m / Capital Employed (Equity 535.0m + L.T.Debt 100.0m))
RoIC = -33.93% (negative operating profit) (NOPAT -267.8m / Invested Capital 789.2m)
WACC = 12.52% (E(3.81b)/V(3.94b) * Re(12.48%) + D(126.0m)/V(3.94b) * Rd(17.46%) * (1-Tc(0.21)))
Discount Rate = 12.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 25.67%
[DCF] Fair Price = unknown (Cash Flow -489.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.38 | # QB: 0
Revenue Correlation: 64.58 | Revenue CAGR: 28.15% | SUE: -0.23 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.81 | Chg30d=-5.07% | Revisions=+25% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.83 | Chg30d=-0.70% | Revisions=+50% | Analysts=7
EPS current Year (2026-12-31): EPS=-3.48 | Chg30d=+0.27% | Revisions=-17% | GrowthEPS=-5.9% | GrowthRev=-65.6%
EPS next Year (2027-12-31): EPS=-3.10 | Chg30d=+1.96% | Revisions=-17% | GrowthEPS=+10.9% | GrowthRev=+9.4%
[Analyst] Revisions Ratio: +15% (up=6, down=4)